Aravive is an endocrine-focused biopharmaceutical company that engaged in developing a long-acting form of recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease that affects pediatric and adult patients. Somavaratan is a fusion protein consisting of rhGH and a proprietary half-life extension technology known as XTEN™. Somavaratan includes a long N-terminal XTEN sequence, XTEN1, which is added to rhGH as a fusion protein, increasing the hydrodynamic size of the rhGH and thereby reducing glomerular filtration. A C-terminal XTEN sequence, XTEN2, is also added to reduce receptor mediated clearance by decreasing receptor binding. We show 20 historical shares outstanding datapoints in our coverage of VSAR's shares outstanding history.
Understanding the changing numbers of VSAR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VSAR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VSAR by allowing them to research VSAR shares outstanding history
as well as any other stock in our coverage universe. |
Free VSAR Email Alerts:
Video: Shares Outstanding Importance
